What is Moravek?
As a premier manufacturer of radiolabeled and stable-labeled compounds, Moravek, Inc. occupies a vital niche in the life sciences sector. The company specializes in the production of GMP carbon-14 labeled active pharmaceutical ingredients (APIs), which are essential for conducting early-phase clinical trials. By leveraging over 45 years of technical expertise, Moravek provides comprehensive custom synthesis, purification, and analytical services to a global clientele of pharmaceutical firms and research institutions. Their commitment to rigorous quality systems and regulatory compliance ensures that they remain a preferred partner for complex drug development projects requiring precise isotopic labeling.
The company's market position is defined by its ability to navigate the stringent requirements of pharmaceutical manufacturing. By maintaining a robust catalog of isotopically labeled compounds, Moravek serves as a foundational element for researchers aiming to track drug metabolism and pharmacokinetics. This operational excellence is supported by a deep understanding of the regulatory landscape, allowing the firm to bridge the gap between laboratory-scale research and clinical-grade production.
How much funding has Moravek raised?
Moravek has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
Key Investors in Moravek
PPP
Public-Private Partnership
What's next for Moravek?
Following this major strategic investment, Moravek is expected to prioritize the scaling of its GMP manufacturing facilities to meet the rising demand for specialized APIs. The infusion of capital will likely facilitate the integration of advanced analytical technologies and the expansion of their custom synthesis capacity, enabling the firm to support more complex clinical trial pipelines. As the pharmaceutical industry continues to emphasize precision medicine and detailed metabolic profiling, Moravek's role as a high-quality supplier becomes increasingly central to the success of new therapeutic candidates. The company is poised to leverage this financial momentum to solidify its leadership in the isotope labeling market, ensuring that it remains at the forefront of pharmaceutical innovation and regulatory compliance.
See full Moravek company page
